You are here

  • Home
  • Archive
  • Volume 11, Issue 3
  • Immune and pathologic responses in patients with localized prostate cancer who received daratumumab (anti-CD38) or edicotinib (CSF-1R inhibitor)

Article metrics

Article menu
Clinical/translational cancer immunotherapy
Original research
Immune and pathologic responses in patients with localized prostate cancer who received daratumumab (anti-CD38) or edicotinib (CSF-1R inhibitor)

 

Online download statistics by month:

Online download statistics by month: March 2023 to July 2025

AbstractFullPdf
Mar 2023324331117
Apr 202325125283
May 202326226251
Jun 202310810815
Jul 202311011035
Aug 202312212217
Sep 2023878724
Oct 2023717425
Nov 202312712830
Dec 202319819949
Jan 2024939342
Feb 2024969639
Mar 202410410482
Apr 202411611639
May 202410210227
Jun 2024737418
Jul 202411411534
Aug 2024198199132
Sep 202415315360
Oct 2024767640
Nov 2024909137
Dec 20249310342
Jan 2025717333
Feb 202519619649
Mar 2025747457
Apr 2025818146
May 2025595931
Jun 2025373718
Jul 2025110
Total348735161272